DOUBLE-STRANDED OLIGO RNA STRUCTURE COMPRISING miRNA

Abstract

The present invention relates to a double-stranded oligo RNA structure comprising double-stranded miRNA, and a composition for preventing or treating cancer, containing the same. More specifically, the present invention relates to an anti-cancer pharmaceutical composition, containing: a double-stranded oligo RNA structure comprising miR-3670, miR-4477a and miR-8078, and characterized by a method for effectively inhibiting cancer cell proliferation or inducing cancer cell apoptosis; and a pharmaceutically acceptable carrier.

What is claimed is: 
     
         1 . A method for treating a lung cancer, comprising administering to a subject in need thereof a double-stranded oligo RNA structure comprising the following Formula (1):
   A-X-R-Y-B   Formula (1)
   wherein A represents a hydrophilic material, B represents a hydrophobic material, X and Y each independently represent a simple covalent bond or a linker-mediated covalent bond, and R represents an miRNA, wherein said miRNA is miR-8078.   
     
     
         2 . The method of  claim 1 , wherein the miRNA treats cancer by inducing apoptosis of cancer cell. 
     
     
         3 . The method of  claim 1 , wherein the hydrophilic material is represented by (A) n , (A m -J) n  or (J-A m ) n , wherein A represents a hydrophilic material monomer, n represents 1 to 200, m represents 1 to 15, and J represents a linker that links m hydrophilic material monomers to one another, or links m hydrophilic material monomers to oligonucleotides. 
     
     
         4 . The method of  claim 1 , wherein the hydrophilic material has a molecular weight of 200 to 10,000. 
     
     
         5 . The method of  claim 1 , wherein the hydrophilic material is polyethylene glycol (PEG). 
     
     
         6 . The method of  claim 3 , wherein the hydrophilic material monomer is the following compound (1): 
       
         
           
           
               
               
           
         
       
       wherein G in Compound (1) is selected from the group consisting of CH 2 , O, S, and NH. 
     
     
         7 . The method of  claim 3 , wherein the linker (J) is selected from the group consisting of PO 3   − , SO 3 , and CO 2 . 
     
     
         8 . The method of  claim 1 , wherein the hydrophobic material has a molecular weight of 250 to 1,000. 
     
     
         9 . The method of  claim 1 , wherein the hydrophobic material is selected from the group consisting of a steroid derivative, a glyceride derivative, glycerol ether, polypropylene glycol, C 12  to C 50  unsaturated or saturated hydrocarbon, diacyl-phosphatidylcholine, fatty acid, phospholipid, and lipopolyamine. 
     
     
         10 . The method of  claim 9 , wherein the steroid derivative is selected from the group consisting of cholesterol, cholestanol, cholic acid, cholesteryl formate, cholestanyl formate and cholestanylamine. 
     
     
         11 . The method of  claim 9 , wherein the glyceride derivative is selected from mono-, di- and tri-glyceride. 
     
     
         12 . The method of  claim 1 , wherein the covalent bond represented by X and Y is a non-degradable or degradable bond. 
     
     
         13 . The method of  claim 12 , wherein the non-degradable bond is an amide bond or a phosphoryl bond. 
     
     
         14 . The method of  claim 12 , wherein the degradable bond is a disulfide bond, an acid-degradable bond, an ester bond, an anhydride bond, a biodegradable bond or an enzyme-degradable bond. 
     
     
         15 . The method of  claim 1 , wherein miR-8078 comprises a double stranded RNA comprising a base sequence of SEQ ID NO. 65; and a base sequence of SEQ ID NO. 66 or SEQ ID NO. 69.